Rybrevant shows colorectal cancer promise in latest bispecifics win

J&J’s Rybrevant is taking on another EGFR standard-of-care therapy in a new indication, with Phase II data that suggest the bispecific renders certain metastatic colorectal patients eligible for curative surgery. The data add more support to the case for targeting two oncogenic pathways with a single compound. 

At the ESMO Conference in Barcelona, Johnson & Johnson (NYSE:JNJ) reported that Rybrevant amivantamab plus chemotherapy — either the mFOLFOX6 or FOLFIRI regimen — led to an objective response rate (ORR) of 49% as first- or second-line therapy for colorectal cancers lacking RAS or BRAF mutations in the Phase II OrigAMI-1 study...